HomeCompareCVTGF vs PFE

CVTGF vs PFE: Dividend Comparison 2026

CVTGF yields 1.32% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CVTGF wins by $73.1K in total portfolio value
10 years
CVTGF
CVTGF
● Live price
1.32%
Share price
$49.00
Annual div
$0.65
5Y div CAGR
60%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$122.7K
Annual income
$52,188.01
Full CVTGF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CVTGF vs PFE

📍 CVTGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCVTGFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CVTGF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CVTGF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CVTGF
Annual income on $10K today (after 15% tax)
$112.55/yr
After 10yr DRIP, annual income (after tax)
$44,359.81/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CVTGF beats the other by $22,039.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CVTGF + PFE for your $10,000?

CVTGF: 50%PFE: 50%
100% PFE50/50100% CVTGF
Portfolio after 10yr
$86.1K
Annual income
$39,223.37/yr
Blended yield
45.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CVTGF
No analyst data
Altman Z
5.5
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CVTGF buys
0
PFE buys
0
No recent congressional trades found for CVTGF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCVTGFPFE
Forward yield1.32%6.13%
Annual dividend / share$0.65$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR60%13.2%
Portfolio after 10y$122.7K$49.6K
Annual income after 10y$52,188.01$26,258.71
Total dividends collected$96.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CVTGF vs PFE ($10,000, DRIP)

YearCVTGF PortfolioCVTGF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,912$211.86$9,153$693.39+$1.8KCVTGF
2$12,021$345.69$8,593$849.25+$3.4KCVTGF
3$13,432$569.48$8,336$1,066.78+$5.1KCVTGF
4$15,324$951.52$8,437$1,384.80+$6.9KCVTGF
5$18,020$1,623.21$9,013$1,875.40+$9.0KCVTGF
6$22,136$2,854.25$10,306$2,680.72+$11.8KCVTGF
7$28,928$5,242.83$12,820$4,101.38+$16.1KCVTGF
8$41,198$10,245.36$17,673$6,826.70+$23.5KCVTGF
9$65,901$21,818.47$27,543$12,591.86+$38.4KCVTGF
10$122,702$52,188.01$49,560$26,258.71+$73.1KCVTGF

CVTGF vs PFE: Complete Analysis 2026

CVTGFStock

Clairvest Group Inc. is a private equity firm specializing in mid-market, growth equity investments, growth capital, buyouts, and consolidating industries and add-on acquisitions. It seeks to invest in small and mid-sized gaming and casino, local market gaming, healthcare, equipment rental, facility services, oilfield services, waste management, business services, consumer services, aerospace, automotive aftermarket, collision repair, food, beverage and co-packing, defense, document management, warranty, contact manufacturing, environmental services, rental services, residential HVAC services, healthcare services, multiunit healthcare, insurance services, IT services, logistics and transportation, mining services, packaging, pest control, specialty aviation, education, software (mature), textile rental, utility services, water, building products, government services, industrial distribution and services, information technology and information services, media and marketing, non-destructive testing, renewable energy, property management, and restaurants. The firm typically invests in companies based in North America including United States and Canada. It seeks to make equity investments between CAD$25 million ($19.53 million) and CAD$100 million ($78.14 million) in its portfolio company with EBITDA between CAD$5 million ($3.81 million) and CAD$50 million ($39.07 million). The firm does not require majority stake and takes controlling or minority investments. It invests its own capital and seeks to take a board seat on its portfolio companies. The firm also makes co-investments. The firm typically exits its investments through market share offering, a strategic sale or sale to a financial buyer. Clairvest Group Inc. was founded in 1987 and is based in Toronto, Canada.

Full CVTGF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CVTGF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CVTGF vs SCHDCVTGF vs JEPICVTGF vs OCVTGF vs KOCVTGF vs MAINCVTGF vs JNJCVTGF vs MRKCVTGF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.